240
Participants
Start Date
May 1, 2024
Primary Completion Date
May 31, 2025
Study Completion Date
May 31, 2028
Serplulimab
Serplulimab will be administered by intravenous infusion at a dose of 300mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
Cisplatin
IV infusion
Carboplatin
IV infusion
Brachytherapy and External Beam Radiotherapy
Brachytherapy and External Beam Radiotherapy
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
OTHER